BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 21812499)

  • 1. Systemic therapies for metastatic renal cell carcinoma in older adults.
    Pal SK; Vanderwalde A; Hurria A; Figlin RA
    Drugs Aging; 2011 Aug; 28(8):635-49. PubMed ID: 21812499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK
    Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of current and future systemic therapy for metastatic renal cell carcinoma.
    Osawa T; Takeuchi A; Kojima T; Shinohara N; Eto M; Nishiyama H
    Jpn J Clin Oncol; 2019 May; 49(5):395-403. PubMed ID: 30722031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of elderly patients with metastatic renal cell carcinoma.
    Zanardi E; Grassi P; Cavo A; Verzoni E; Maggi C; De Braud F; Boccardo F; Procopio G
    Expert Rev Anticancer Ther; 2016; 16(3):323-34. PubMed ID: 26654225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for metastatic renal cell carcinoma.
    Unverzagt S; Moldenhauer I; Nothacker M; Roßmeißl D; Hadjinicolaou AV; Peinemann F; Greco F; Seliger B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD011673. PubMed ID: 28504837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study.
    Guo J; Huang Y; Zhang X; Zhou F; Sun Y; Qin S; Ye Z; Wang H; Jappe A; Straub P; Pirotta N; Gogov S
    BMC Cancer; 2013 Mar; 13():136. PubMed ID: 23514360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenging the treatment paradigm for advanced renal cell carcinoma: a review of systemic and localized therapies.
    Bex A; Larkin J; Voss M
    Am Soc Clin Oncol Educ Book; 2015; ():e239-47. PubMed ID: 25993179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Local Intervention Combined with Targeted Therapy on Metastatic Renal Cell Carcinoma.
    Li JR; Ou YC; Yang CK; Wang SS; Chen CS; Ho HC; Cheng CL; Yang CR; Chen CC; Wang SC; Lin CY; Hung SC; Hsu CY; Chiu KY
    Anticancer Res; 2018 Sep; 38(9):5339-5345. PubMed ID: 30194186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint Inhibitors.
    Esther J; Hale P; Hahn AW; Agarwal N; Maughan BL
    Drugs Aging; 2019 May; 36(5):395-401. PubMed ID: 30784023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction.
    Gupta S; Parsa V; Heilbrun LK; Smith DW; Dickow B; Heath E; Vaishampayan U
    Anticancer Drugs; 2011 Sep; 22(8):794-800. PubMed ID: 21799472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in metabolic profile, iron and ferritin levels during the treatment of metastatic renal cancer - A new potential biomarker?
    Golčić M; Petković M
    Med Hypotheses; 2016 Sep; 94():148-50. PubMed ID: 27515221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era.
    Pal SK; Nelson RA; Vogelzang N
    PLoS One; 2013; 8(5):e63341. PubMed ID: 23658823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of available treatment options for renal cell carcinoma.
    Derosa L; Albiges L; Massard C; Loriot Y; Fizazi K; Escudier B
    Expert Opin Drug Saf; 2016 Aug; 15(8):1097-106. PubMed ID: 27142582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Examining the bleeding incidences associated with targeted therapies used in metastatic renal cell carcinoma.
    Crist M; Hansen E; Chablani L; Guancial E
    Crit Rev Oncol Hematol; 2017 Dec; 120():151-162. PubMed ID: 29198329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery.
    Verzoni E; Ratta R; Grassi P; Salvioni R; Stagni S; Montone R; Fucà G; Cappelletti V; Reduzzi C; De Giorgi U; Procopio G
    Tumori; 2018 Oct; 104(5):401-405. PubMed ID: 29192741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature.
    Overby A; Duval L; Ladekarl M; Laursen BE; Donskov F
    Clin Genitourin Cancer; 2019 Feb; 17(1):e32-e37. PubMed ID: 30268423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of age on treatment trends and clinical outcome in patients with metastatic renal cell carcinoma.
    Pal SK; Hsu J; Hsu S; Hu J; Bergerot P; Carmichael C; Saikia J; Liu X; Lau C; Twardowski P; Figlin RA; Yuh BF
    J Geriatr Oncol; 2013 Apr; 4(2):128-33. PubMed ID: 23646100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
    Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
    J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.
    Albiges L; Fay AP; Xie W; Krajewski K; McDermott DF; Heng DY; Dariane C; DeVelasco G; Lester R; Escudier B; Choueiri TK
    Eur J Cancer; 2015 Nov; 51(17):2580-6. PubMed ID: 26346135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
    Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
    Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.